<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168273">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02046499</url>
  </required_header>
  <id_info>
    <org_study_id>PPH Prevention Trial</org_study_id>
    <nct_id>NCT02046499</nct_id>
  </id_info>
  <brief_title>A Randomized Trial Comparing Oxytocin and Oxytocin + Ergometrine for Prevention of Postpartum Haemorrhage at Caesarean Section</brief_title>
  <official_title>A Randomized Trial Comparing Oxytocin and Oxytocin + Ergometrine for Prevention of Postpartum Haemorrhage at Caesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pretoria</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pretoria</source>
  <oversight_info>
    <authority>South Africa: Human Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized trial comparing oxytocin versus oxytocin + syntometrine in the
      prevention of post partum haemorrhage in patients undergoing caesarean section
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Blood loss</measure>
    <time_frame>60 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Estimated blood loss at caesarean section</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Side effects of oxytocin compared to oxytocin + ergometrine</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Compare side effects experienced by women administered oxytocin compared to oxytocin plus ergometrine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for additional uterotonics</measure>
    <time_frame>60 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine the need for additional uterotonics to treat post partum haemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of units blood transfused</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare the number of units blood required for transfusion between the two arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Prevention of Post Partum Haemorrhage</condition>
  <arm_group>
    <arm_group_label>Oxytocin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxytocin alone administered which is current standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxytocin + syntometrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin plus syntometrine administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>Oxytocin will be administered intravenously as per standard protocol</description>
    <arm_group_label>Oxytocin arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin ergometrine</intervention_name>
    <description>Oxytocin ergometrine will be administered intra-musculalry</description>
    <arm_group_label>Oxytocin + syntometrine</arm_group_label>
    <other_name>Syntometrine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women delivering by caesarean section older than 18 years willing and able
             to give informed consent

        Exclusion Criteria:

          -  • Women not willing or women not able to provide consent

               -  Women who have a classical caesarean section

               -  Women younger than 18 years of age

               -  Women with any of the following conditions will be excluded (ergometrine
                  contra-indicated in patients with these conditions).

               -  Pre- eclampsia

               -  Eclampsia,

               -  Uncontrolled hypertension (hypertension defined as systolic blood pressure more
                  than 140 mm Hg and diastolic blood pressure more than 90 mm Hg)

               -  Any cardiac lesion

               -  Impaired liver function

               -  Impaired kidney function

               -  Hypersensitivity to any of the active ingredients of the preparations that will
                  be used (Syntometrine® or Syntocinon®)

               -  Occlusive vascular disease

               -  Autoimmune vasculitis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leon C Snyman, MbChB MMed</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department Obstetrics &amp; Gynaecology, University of Pretoria, South Africa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leon C Snyman, MBChB, MMed</last_name>
    <phone>+27834621818</phone>
    <email>leon.snyman@up.ac.za</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandy Koen, MBChB</last_name>
    <phone>+27767903940</phone>
    <email>sandy.koen@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kalafong Academic Hospital</name>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <zip>0001</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sandy Koen, MBChB</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 23, 2014</lastchanged_date>
  <firstreceived_date>January 23, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pretoria</investigator_affiliation>
    <investigator_full_name>Leon Snyman</investigator_full_name>
    <investigator_title>Principal Specialist</investigator_title>
  </responsible_party>
  <keyword>Prevention, post partum haemorrhage</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ergonovine</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
    <mesh_term>Syntometrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
